Every Form 4 that Zevra Therapeutics Inc (ZVRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZVRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZVRA filings page.
Zevra Therapeutics, Inc. (ZVRA) insider Rahsaan Thompson, Chief Legal & Compliance officer, reported selling 42,666 shares of common stock on 2026-08-14 in an open-market transaction under a Rule 10b5-1(c) trading plan. The weighted average sale price was $11.1277 per share, and Thompson now holds 37,569 shares directly.
The sales were executed in multiple trades at prices between $10.86 and $11.36, with the weighted average reported. The referenced Rule 10b5-1(c) plan had an adoption date of 05-15-2026.
Director Corey Michael Watton of Zevra Therapeutics, Inc. exercised stock options for 12,300 shares of common stock at an exercise price of $4.97 per share and on the same date sold 12,300 shares of common stock at a weighted average price of $11.2502 per share, in multiple trades ranging from $11.23 to $11.31. Following the option exercise, Watton held 46,500 stock options that remain outstanding and fully vested under the reported award.
Zevra Therapeutics, Inc. reported that Chief Legal & Compliance Officer Rahsaan Thompson exercised equity awards and sold shares. On June 21, 2026, he exercised 66,667 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share. After this exercise, his direct holdings were 114,792 common shares. On June 22, 2026, he completed an open-market sale of 34,557 common shares at a weighted average price of $12.6835 per share, leaving him with 80,235 common shares held directly. Footnotes explain that each restricted stock unit converts into one common share and outline a vesting schedule for the RSU grant, as well as a referenced Rule 10b5-1(c) plan adoption date.
Zevra Therapeutics director Tamara A. Favorito received a grant of stock options for 30,000 shares of common stock on June 4, 2026. The options have an exercise price of $11.17, matching the Nasdaq closing price on the grant date, and expire on June 3, 2036. All 30,000 shares underlying the options vest 100% on the earlier of the first anniversary of the grant, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, subject to her continued board service. The grant was awarded as compensation under Zevra’s non-employee director compensation policy.
Zevra Therapeutics director Alicia Secor received a grant of stock options to acquire 30,000 shares of common stock as compensation for her board service. The options have an exercise price of $11.17 per share, equal to the June 4, 2026 closing price, vest 100% upon the earliest of specified service-based dates, and expire on June 3, 2036.
Zevra Therapeutics director Corey Michael Watton received a grant of stock options for 30,000 shares of common stock. The options have an exercise price of $11.17 per share, matching the June 4, 2026 Nasdaq closing price, and expire on June 3, 2036.
This award was granted as compensation for his service on the board under Zevra’s non-employee director compensation policy, not through open-market buying. All 30,000 options vest 100% on the earlier of the first anniversary of the grant, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, assuming continued board service.
Zevra Therapeutics director Douglas W. Calder received a grant of stock options as board compensation. The award covers 30,000 options to buy common stock at an exercise price of $11.17 per share, matching the Nasdaq closing price on June 4, 2026.
All 30,000 options vest 100% on the earlier of the first anniversary of grant, the day before the first annual stockholders meeting after the grant date, or immediately before a change in control, subject to continued service. Following this grant, Calder holds 30,000 options directly.
Zevra Therapeutics, Inc. director Thomas Anderson received a grant of stock options covering 30,000 shares of common stock as compensation for his board service. The options have an exercise price of $11.17 per share, matching the Nasdaq closing price on June 4, 2026, and expire on June 3, 2036. All 30,000 options vest 100% on the earlier of the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, subject to his continued service.
Zevra Therapeutics director Alvin Shih received a grant of 30,000 stock options to buy common stock at an exercise price equal to the Nasdaq closing price of $11.17 on June 4, 2026. The options vest 100% on the earlier of the first anniversary, the day before the first annual stockholders meeting after grant, or immediately before a change in control, subject to his continued board service, and expire on June 3, 2036.
Zevra Therapeutics senior vice president of finance and corporate controller Timothy J. Sangiovanni received new equity awards. He was granted 20,000 restricted stock units, each representing one share of common stock, and a stock option for 40,000 shares at an exercise price of $11.40 per share. The option vests in four equal annual installments beginning on March 1, 2027, while the restricted stock units vest one third on March 1, 2027 and the remaining two thirds in equal annual installments thereafter, in each case subject to his continued service.
Zevra Therapeutics Chief Legal & Compliance officer Rahsaan Thompson reported an open-market sale of 1,794 shares of common stock at $11.30 per share. After this transaction, he directly holds 48,125 shares. The sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on 01-08-2026, indicating it was pre-scheduled rather than a discretionary trade.
Zevra Therapeutics director John B. Bode exercised stock options to acquire 78,400 shares of common stock. On March 24, 2026, he exercised two option grants covering 39,200 shares each at exercise prices of $4.97 and $4.89 per share.
Following these exercises, Bode directly owns 123,400 shares of Zevra Therapeutics common stock. The transactions were reported as derivative exercises rather than open-market purchases or sales, indicating a shift from options-based compensation into outright share ownership.
Zevra Therapeutics, Inc. reported that its CFO, Justin A. Renz, received a grant of stock options to purchase 300,000 shares of common stock. The options have an exercise price of $9.55 per share, equal to the closing market price on March 18, 2026, and expire ten years after the grant date.
The award was made under Zevra’s 2023 Employment Inducement Award Plan and vests in four equal annual installments beginning on the first anniversary of the grant, subject to continued service. All underlying shares will vest in full immediately before a change of control, and vesting will be accelerated by 12 months if the CFO is terminated without cause or resigns for good reason.
Zevra Therapeutics President and CEO Neil F. McFarlane reported equity award vesting and a planned share sale. On February 7, 2026, 37,500 restricted stock units vested, converting into the same number of common shares as part of an award that vests in three annual installments.
On February 9, 2026, McFarlane sold 14,625 shares of common stock at a weighted average price of $8.5597 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 21, 2025. Following these transactions, he directly holds 387,225 common shares and 75,000 restricted stock units.
Zevra Therapeutics SVP, Finance & Corp Controller Timothy J. Sangiovanni reported a planned stock sale. On 02/03/2026, he sold 3,000 shares of Zevra Therapeutics common stock in open-market transactions at a weighted average price of $9.1827 per share.
The trades were executed in multiple lots at prices ranging from $8.93 to $9.52, and were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on 03/28/2025. After this sale, he directly beneficially owns 29,590 Zevra common shares.
Zevra Therapeutics’ Chief Commercial Officer Joshua Schafer reported a pre-planned stock sale. On 02/03/2026, he sold 10,500 shares of Zevra Therapeutics common stock at a weighted average price of $9.1905 per share under a Rule 10b5-1(c) trading plan adopted on 03/27/2025. After this sale, he beneficially owned 62,278 shares held directly.
Zevra Therapeutics SVP Timothy J. Sangiovanni reported stock transactions involving common shares and restricted stock units. On January 30, 2026, he settled 6,333 restricted stock units into common stock and sold 1,750 shares at a weighted average price of $8.824 under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 28, 2025.
On January 31, 2026, he settled another 11,666 restricted stock units into common stock. Following these transactions, he directly beneficially owned 32,590 shares of common stock and held remaining restricted stock units that continue to vest over time, subject to his continued service.
Zevra Therapeutics insider Rahsaan W. Thompson, the Chief Legal & Compliance Officer and Secretary, reported multiple equity transactions in late January 2026. On January 29, he received 37,500 restricted stock units, which start vesting on January 29, 2027 in yearly installments, and a stock option for 75,000 shares at $8.86 per share that vests over four years and expires in 2036.
On January 30, one third of a prior restricted stock unit grant, or 11,333 units, vested and converted into common shares. The same day, he sold 4,080 common shares at a weighted average price of $8.8259 under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025, leaving him with 49,919 common shares held directly.
Zevra Therapeutics’ Chief Medical Officer, Adrian W. Quartel, reported several equity transactions. On January 29, 2026, he received 37,500 restricted stock units (RSUs), each representing one share of common stock, and a stock option for 75,000 shares at an exercise price of $8.86.
The new RSUs will vest one third on January 29, 2027, with the remaining two thirds vesting in equal annual installments, subject to continued service. The stock option vests in four equal annual installments beginning on the first anniversary of the grant date, also subject to continued service.
On January 30, 2026, 11,333 RSUs vested and settled into common shares, and Quartel sold 4,533 shares at a weighted average price of $8.8321 under a Rule 10b5‑1(c) trading plan adopted on March 26, 2025, leaving 9,723 common shares held directly and 22,667 RSUs outstanding.
Zevra Therapeutics chief commercial officer Joshua Schafer reported multiple equity compensation events and a small share sale. On January 29, he received 37,500 restricted stock units and a stock option for 75,000 shares at $8.86 per share. On January 30, 11,333 RSUs vested and converted into common stock, and he sold 3,375 shares at a weighted average price of $8.8297 under a pre‑adopted Rule 10b5‑1(c) trading plan dated March 27, 2025. On January 31, a further 35,334 RSUs vested into common stock. The new RSU and option awards vest in multi‑year installments, contingent on his continued service.
Zevra Therapeutics President and CEO Neil F. McFarlane, who also serves as a director, reported several equity transactions. On February 2, 2026, he sold 91,000 shares of common stock at a weighted average price of $9.3783 per share under a Rule 10b5-1(c) trading plan adopted on March 21, 2025, leaving him with 364,350 common shares held directly.
On January 31, 2026, 233,334 restricted stock units (RSUs) vested and settled into the same number of common shares, increasing his directly held common stock to 455,350 shares before the subsequent sale and reducing his RSU balance to 233,333 units. Earlier, on January 29, 2026, he received equity awards of 125,000 RSUs and a 250,000-share stock option with a $8.86 exercise price, each subject to multi‑year vesting tied to continued service.
Zevra Therapeutics former CFO & Treasurer Clifton R. LaDuane reported equity transactions tied to his departure on December 31, 2025. On that date, 140,667 shares of common stock were issued at $0 upon vesting of previously granted restricted stock units and performance stock units. After this issuance, he held 192,028 common shares.
Also on December 31, 2025, 48,513 common shares were withheld at $8.96 per share to cover withholding taxes related to the vesting, leaving him with 143,515 common shares beneficially owned directly. The filing shows 86,667 and 34,000 restricted stock units and 20,000 performance stock units converting into common stock, with all such units fully vested and accelerated upon his departure, and no derivative units remaining.
Neil F. McFarlane, President and CEO of Zevra Therapeutics, Inc. (ZVRA), reported equity transactions on 10/10/2025. He received 50,000 restricted stock units (RSUs) that vested and settled under the company plan, bringing his direct holding to 241,516 shares. On the same date he sold 19,500 shares at a price of $10.8158, leaving him with 222,016 shares. The RSUs were part of an inducement award where 25% vested and settled on 10/10/2024 and another 25% on 10/10/2025, with the remaining 50% vesting in equal annual installments thereafter subject to continued employment; full vesting also occurs on a change of control or certain termination events. The sale was made pursuant to a 10b5-1(c) plan adopted 03/21/2025.
Tamara A. Favorito, a director of ZEVRA THERAPEUTICS, INC. (ZVRA), purchased 3,175 shares of the company's common stock on 09/12/2025 at a reported price of $7.7852 per share. After the transaction, Ms. Favorito beneficially owned 3,894 shares. The Form 4 was executed by Timothy J. Sangiovanni as attorney-in-fact and dated 09/16/2025.